Genetic engineering of mesenchymal stem cells and its application in human disease therapy
- PMID: 20825283
- PMCID: PMC2978545
- DOI: 10.1089/hum.2010.165
Genetic engineering of mesenchymal stem cells and its application in human disease therapy
Abstract
The use of stem cells for tissue regeneration and repair is advancing both at the bench and bedside. Stem cells isolated from bone marrow are currently being tested for their therapeutic potential in a variety of clinical conditions including cardiovascular injury, kidney failure, cancer, and neurological and bone disorders. Despite the advantages, stem cell therapy is still limited by low survival, engraftment, and homing to damage area as well as inefficiencies in differentiating into fully functional tissues. Genetic engineering of mesenchymal stem cells is being explored as a means to circumvent some of these problems. This review presents the current understanding of the use of genetically engineered mesenchymal stem cells in human disease therapy with emphasis on genetic modifications aimed to improve survival, homing, angiogenesis, and heart function after myocardial infarction. Advancements in other disease areas are also discussed.
Figures
Similar articles
-
From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells.J Cell Physiol. 2007 Apr;211(1):27-35. doi: 10.1002/jcp.20959. J Cell Physiol. 2007. PMID: 17226788 Review.
-
The therapeutic potential of mesenchymal stem cells for cardiovascular diseases.Cell Death Dis. 2020 May 11;11(5):349. doi: 10.1038/s41419-020-2542-9. Cell Death Dis. 2020. PMID: 32393744 Free PMC article. Review.
-
Concise review: mesenchymal stromal cells: potential for cardiovascular repair.Stem Cells. 2008 Sep;26(9):2201-10. doi: 10.1634/stemcells.2008-0428. Epub 2008 Jul 3. Stem Cells. 2008. PMID: 18599808 Review.
-
Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine.J Cell Mol Med. 2009 Nov-Dec;13(11-12):4385-402. doi: 10.1111/j.1582-4934.2009.00857.x. Epub 2009 Jul 10. J Cell Mol Med. 2009. PMID: 19602034 Free PMC article. Review.
-
Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors.Adv Drug Deliv Rev. 2010 Sep 30;62(12):1167-74. doi: 10.1016/j.addr.2010.09.013. Epub 2010 Oct 13. Adv Drug Deliv Rev. 2010. PMID: 20920540 Free PMC article. Review.
Cited by
-
GABARAP ameliorates IL-1β-induced inflammatory responses and osteogenic differentiation in bone marrow-derived stromal cells by activating autophagy.Sci Rep. 2021 Jun 2;11(1):11561. doi: 10.1038/s41598-021-90586-9. Sci Rep. 2021. PMID: 34078931 Free PMC article.
-
In vitro augmentation of mesenchymal stem cells viability in stressful microenvironments : In vitro augmentation of mesenchymal stem cells viability.Cell Stress Chaperones. 2015 Mar;20(2):237-51. doi: 10.1007/s12192-014-0560-1. Epub 2014 Dec 20. Cell Stress Chaperones. 2015. PMID: 25527070 Free PMC article. Review.
-
HASF is a stem cell paracrine factor that activates PKC epsilon mediated cytoprotection.J Mol Cell Cardiol. 2014 Jan;66:157-64. doi: 10.1016/j.yjmcc.2013.11.010. Epub 2013 Nov 20. J Mol Cell Cardiol. 2014. PMID: 24269490 Free PMC article.
-
Improvement of Liver Transplantation Outcome by Heme Oxygenase-1-Transduced Bone Marrow Mesenchymal Stem Cells in Rats.Stem Cells Int. 2016;2016:9235073. doi: 10.1155/2016/9235073. Epub 2016 Jan 5. Stem Cells Int. 2016. PMID: 26862332 Free PMC article.
-
Applications of synthetic biology in medical and pharmaceutical fields.Signal Transduct Target Ther. 2023 May 11;8(1):199. doi: 10.1038/s41392-023-01440-5. Signal Transduct Target Ther. 2023. PMID: 37169742 Free PMC article. Review.
References
-
- Abdallah B.M. Haack-Sorensen M. Burns J.S. Elsnab B. Jakob F. Hokland P. Kassem M. Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite [corrected] extensive proliferation. Biochem. Biophys. Res. Commun. 2005;326:527–538. - PubMed
-
- Aguayo-Mazzucato C. Bonner-Weir S. Stem cell therapy for type 1 diabetes mellitus. Nat. Rev. Endocrinol. 2010;6:139–148. - PubMed
-
- Arguero R. Careaga-Reyna G. Castano-Guerra R. Garrido-Garduno M.H. Magana-Serrano J.A. de Jesus Nambo-Lucio M. Cellular autotransplantation for ischemic and idiopathic dilated cardiomyopathy: Preliminary report. Arch. Med. Res. 2006;37:1010–1014. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources